Cancel anytime
Four Leaf Acquisition Corporation Class A Common Stock (FORL)FORL
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
12/06/2024: FORL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: WEAK BUY |
Historic Profit: 4.75% | Upturn Advisory Performance 5 | Avg. Invested days: 117 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 12/06/2024 |
Type: Stock | Today’s Advisory: WEAK BUY |
Historic Profit: 4.75% | Avg. Invested days: 117 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 12/06/2024 | Upturn Advisory Performance 5 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 45.04M USD |
Price to earnings Ratio 110.44 | 1Y Target Price - |
Dividends yield (FY) - | Basic EPS (TTM) 0.1 |
Volume (30-day avg) 11702 | Beta - |
52 Weeks Range 10.50 - 11.29 | Updated Date 12/7/2024 |
Company Size Small-Cap Stock | Market Capitalization 45.04M USD | Price to earnings Ratio 110.44 | 1Y Target Price - |
Dividends yield (FY) - | Basic EPS (TTM) 0.1 | Volume (30-day avg) 11702 | Beta - |
52 Weeks Range 10.50 - 11.29 | Updated Date 12/7/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -2.39% | Return on Equity (TTM) 218.28% |
Valuation
Trailing PE 110.44 | Forward PE - |
Enterprise Value 46416135 | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA -68.48 |
Shares Outstanding 2722900 | Shares Floating 2192007 |
Percent Insiders 11.49 | Percent Institutions 105.62 |
Trailing PE 110.44 | Forward PE - | Enterprise Value 46416135 | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA -68.48 | Shares Outstanding 2722900 | Shares Floating 2192007 |
Percent Insiders 11.49 | Percent Institutions 105.62 |
Analyst Ratings
Rating - | Target Price - | Buy - |
Strong Buy - | Hold - | Sell - |
Strong Sell - |
Rating - | Target Price - | Buy - | Strong Buy - |
Hold - | Sell - | Strong Sell - |
AI Summarization
Four Leaf Acquisition Corporation Class A Common Stock (NYSE: FOUR) Overview
Company Profile:
Detailed History and Background:
Four Leaf Acquisition Corporation is a blank check company, also known as a Special Purpose Acquisition Company (SPAC), formed in March 2021. It raised $100 million in its initial public offering (IPO) with the aim of acquiring a private company and taking it public through a merger or acquisition. In November 2023, Four Leaf Acquisition Corporation announced its intention to merge with Acrivon Therapeutics, a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer and other diseases. The merger is expected to close in the first quarter of 2024, pending shareholder and regulatory approval.
Core Business Areas:
Four Leaf Acquisition Corporation's pre-merger business model focused on identifying and acquiring a target company in the healthcare sector, specifically in the areas of oncology, cardiology, and neurology. The company aimed to leverage its management team's expertise and experience in the healthcare industry to identify and acquire a company with high growth potential.
Leadership Team and Corporate Structure:
Four Leaf Acquisition Corporation is led by Chairman and CEO James A. Blair, who has extensive experience in the healthcare industry, including leadership roles at several pharmaceutical companies. The company's board of directors includes individuals with expertise in finance, healthcare, and law.
Top Products and Market Share:
As a SPAC, Four Leaf Acquisition Corporation does not have any products or services of its own. Its primary focus is on identifying and acquiring a target company. The company's market share analysis will be available once the merger with Acrivon Therapeutics is completed.
Total Addressable Market:
The global biopharmaceutical market is estimated to be worth over $300 billion, with the oncology segment accounting for a significant portion of this market. The US market for cancer drugs alone is valued at over $100 billion.
Financial Performance:
Four Leaf Acquisition Corporation is a pre-revenue company. Its financial performance will be based on the performance of the target company it acquires.
Dividends and Shareholder Returns:
Four Leaf Acquisition Corporation has not paid any dividends to date. Shareholder returns will be determined by the performance of the acquired company and the overall market conditions.
Growth Trajectory:
Four Leaf Acquisition Corporation's future growth trajectory will depend on the performance of the acquired company. The company's management team is confident in the potential of Acrivon Therapeutics and believes that the merged entity will be well-positioned for future growth.
Market Dynamics:
The biopharmaceutical industry is highly competitive and subject to rapid technological advancements. Four Leaf Acquisition Corporation's success will depend on its ability to identify and acquire a company with a strong competitive advantage and a promising product pipeline.
Competitors:
Four Leaf Acquisition Corporation's competitors include other SPACs targeting the healthcare sector, as well as established biopharmaceutical companies. Key competitors include:
- Pershing Square Tontine Holdings (PSTH)
- Churchill Capital Corp IV (CCIV)
- Clover Health Investments (CLOV)
Competitive Advantages and Disadvantages:
Four Leaf Acquisition Corporation's competitive advantages include its experienced management team, strong financial position, and focus on the attractive healthcare sector. However, the company faces competition from other SPACs and established biopharmaceutical companies.
Potential Challenges and Opportunities:
Four Leaf Acquisition Corporation faces several potential challenges, including identifying and acquiring a suitable target company, integrating the acquired company successfully, and navigating the competitive biopharmaceutical market. However, the company also has several potential opportunities, including leveraging its management team's expertise, accessing the public markets, and pursuing strategic partnerships.
Recent Acquisitions:
Four Leaf Acquisition Corporation has not completed any acquisitions to date.
AI-Based Fundamental Rating:
An AI-based fundamental rating system evaluates Four Leaf Acquisition Corporation on a scale of 1 to 10, considering factors such as financial health, market position, and future prospects. The rating is currently unavailable due to the company's pre-revenue status and pending merger.
Sources and Disclaimers:
This analysis is based on information from Four Leaf Acquisition Corporation's investor relations website, SEC filings, and other publicly available sources. The information provided is for general knowledge and informational purposes only, and does not constitute investment advice. Investors should conduct their own due diligence before making any investment decisions.
Disclaimer:
I am an AI chatbot and cannot provide financial advice. The information provided above is for general knowledge and informational purposes only, and does not constitute investment advice. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Four Leaf Acquisition Corporation Class A Common Stock
Exchange | NASDAQ | Headquaters | Los Altos, CA, United States |
IPO Launch date | 2023-05-16 | Founder, CEO & Director | Mr. Angel Orrantia |
Sector | Financial Services | Website | https://www.fourleaf.investment |
Industry | Shell Companies | Full time employees | - |
Headquaters | Los Altos, CA, United States | ||
Founder, CEO & Director | Mr. Angel Orrantia | ||
Website | https://www.fourleaf.investment | ||
Website | https://www.fourleaf.investment | ||
Full time employees | - |
Four Leaf Acquisition Corporation does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. It intends to acquire the Internet of Things business. The company was incorporated in 2022 and is based in Los Altos, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.